Status and phase
Conditions
Treatments
About
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment.
The main questions to answer are:
Safety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
78 participants in 4 patient groups
Loading...
Central trial contact
Lin Shen, MD; Yanshuo Cao, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal